Compass Return On Tangible Assets from 2010 to 2025

CMPX Stock  USD 2.97  0.14  4.50%   
Compass Therapeutics Return On Tangible Assets yearly trend continues to be fairly stable with very little volatility. Return On Tangible Assets will likely drop to -0.26 in 2025. Return On Tangible Assets is a profitability metric that measures a company's ability to generate earnings from its tangible assets. View All Fundamentals
 
Return On Tangible Assets  
First Reported
2010-12-31
Previous Quarter
(0.24)
Current Value
(0.26)
Quarterly Volatility
0.22458359
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.5 M or Interest Income of 9.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.26. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Latest Compass Therapeutics' Return On Tangible Assets Growth Pattern

Below is the plot of the Return On Tangible Assets of Compass Therapeutics over the last few years. It is a profitability metric that measures a company's ability to generate earnings from its tangible assets. Compass Therapeutics' Return On Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Return On Tangible Assets10 Years Trend
Slightly volatile
   Return On Tangible Assets   
       Timeline  

Compass Return On Tangible Assets Regression Statistics

Arithmetic Mean(0.53)
Geometric Mean0.49
Coefficient Of Variation(42.10)
Mean Deviation0.15
Median(0.59)
Standard Deviation0.22
Sample Variance0.05
Range0.9593
R-Value0.49
Mean Square Error0.04
R-Squared0.24
Significance0.06
Slope0.02
Total Sum of Squares0.76

Compass Return On Tangible Assets History

2025 -0.26
2024 -0.24
2023 -0.27
2022 -0.18
2021 -0.54
2020 -0.57
2019 -1.14

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Return On Tangible Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.24)(0.26)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.